Renaud Sabatier
@renosabat.bsky.social
Medical oncologist focused on gyne
French Guy from the south - Marseille
French Guy from the south - Marseille
Reposted by Renaud Sabatier
🧬 Il est temps de finaliser votre abstract !
👉 Date limite : 14 novembre 2025 (inclus, à minuit CEST)
📩 Les abstracts sélectionnés seront annoncés en décembre 2025.
🎓 Symposium du CRCM — 4–6 février 2026, Marseille
#CRCM #CancerResearch #CRCMSymposium2026
👉 Date limite : 14 novembre 2025 (inclus, à minuit CEST)
📩 Les abstracts sélectionnés seront annoncés en décembre 2025.
🎓 Symposium du CRCM — 4–6 février 2026, Marseille
#CRCM #CancerResearch #CRCMSymposium2026
🎓 SAVE THE DATE – CRCM Symposium 2026
📅 Feb 4–6, 2026
📍 Palais du Pharo, Marseille
The first CRCM Symposium will gather scientists to discuss key advances in cancer research, from cell communication to innovative therapies.
👉 More here: crcm-symposium.com
#CRCM #CancerResearch #Symposium
📅 Feb 4–6, 2026
📍 Palais du Pharo, Marseille
The first CRCM Symposium will gather scientists to discuss key advances in cancer research, from cell communication to innovative therapies.
👉 More here: crcm-symposium.com
#CRCM #CancerResearch #Symposium
November 6, 2025 at 3:24 PM
🧬 Il est temps de finaliser votre abstract !
👉 Date limite : 14 novembre 2025 (inclus, à minuit CEST)
📩 Les abstracts sélectionnés seront annoncés en décembre 2025.
🎓 Symposium du CRCM — 4–6 février 2026, Marseille
#CRCM #CancerResearch #CRCMSymposium2026
👉 Date limite : 14 novembre 2025 (inclus, à minuit CEST)
📩 Les abstracts sélectionnés seront annoncés en décembre 2025.
🎓 Symposium du CRCM — 4–6 février 2026, Marseille
#CRCM #CancerResearch #CRCMSymposium2026
Reposted by Renaud Sabatier
Today @nejm.org
Challenging dogma for routine surveillance imaging after cancer treatment
The results of 12 randomized trials show no survival benefit, despite scans leading to more chemotherapy, surgery and radiation
nejm.org/doi/full/10....
Challenging dogma for routine surveillance imaging after cancer treatment
The results of 12 randomized trials show no survival benefit, despite scans leading to more chemotherapy, surgery and radiation
nejm.org/doi/full/10....
April 26, 2025 at 2:05 PM
Today @nejm.org
Challenging dogma for routine surveillance imaging after cancer treatment
The results of 12 randomized trials show no survival benefit, despite scans leading to more chemotherapy, surgery and radiation
nejm.org/doi/full/10....
Challenging dogma for routine surveillance imaging after cancer treatment
The results of 12 randomized trials show no survival benefit, despite scans leading to more chemotherapy, surgery and radiation
nejm.org/doi/full/10....
Practical clinical management of ocular adverse events related to Anti... sciencedirect.com/science/articl…
Take a look at our latest review about ocular toxicities o#ADCsCs i#gyncsmsm
@paoli-calmettes.bsky.social @crcm.bsky.social @oncoalert.bsky.social !
Take a look at our latest review about ocular toxicities o#ADCsCs i#gyncsmsm
@paoli-calmettes.bsky.social @crcm.bsky.social @oncoalert.bsky.social !
https://sciencedirect.com/science/articl…
March 2, 2025 at 8:56 AM
Practical clinical management of ocular adverse events related to Anti... sciencedirect.com/science/articl…
Take a look at our latest review about ocular toxicities o#ADCsCs i#gyncsmsm
@paoli-calmettes.bsky.social @crcm.bsky.social @oncoalert.bsky.social !
Take a look at our latest review about ocular toxicities o#ADCsCs i#gyncsmsm
@paoli-calmettes.bsky.social @crcm.bsky.social @oncoalert.bsky.social !